Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial.

Deborah Cromer; Arnold Reynaldi; Megan Steain; James A Triccas; Miles Philip Davenport; David S Khoury

This article is a Preprint

Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.

Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial.

Deborah Cromer; Arnold Reynaldi; Megan Steain; James A Triccas; Miles Philip Davenport; David S Khoury.

Affiliation

Deborah Cromer; Kirby Institute, University of New South Wales, Sydney, Australia
Arnold Reynaldi; Kirby Institute, University of New South Wales, Sydney, Australia
Megan Steain; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
James A Triccas; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Miles Philip Davenport; Kirby Institute, UNSW Sydney
David S Khoury; Kirby Institute, University of New South Wales, Sydney, Australia

Preprint in English | medRxiv | ID: ppmedrxiv-21259504

Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article

ABSTRACT

ABSTRACT

A recent study analysed the relationship between neutralising antibody response and protection from SARS-CoV-2 infection across eight vaccine platforms1. The efficacy results from a phase 2b/3 trial of a ninth vaccine candidate, CVnCoV (CUREVAC), was announced on 16 June 20212. The low efficacy of this new mRNA vaccine, which showed only 47% protection from symptomatic SARS-CoV-2 infection, was surprising given the high efficacy of two previous mRNA-based vaccines3,4. A number of factors have been suggested to play a role in the low efficacy in the CVnCoV study, particularly around the dose and immunogenicity of the vaccine (which uses an unmodified mRNA construct5,6) and the potential role of infection with SARS-CoV-2 variants (which were the dominant strains observed in the CVnCoV trial)2.

License

cc_no

Fulltext

Add to My VHL

XML

Search on Google

Full text: Available Collection: Preprints Database: medRxiv Type of study: Rct Language: English Year: 2021 Document type: Preprint

Fulltext

Add to My VHL

XML

Search on Google

Full text: Available Collection: Preprints Database: medRxiv Type of study: Rct Language: English Year: 2021 Document type: Preprint